BPC-157: The Complete Guide to Body Protection Compound 157 -- Dosage, Benefits, and Research

BPC-157 has the unusual distinction of being both the most-studied recovery peptide in the world and one of the most over-claimed compounds on the wellness internet. Both things are true at once. The published research base -- almost all of it preclinical -- is genuinely impressive. The internet noise about it is genuinely overblown. Our job in this guide is to give you the honest middle: what the science actually shows, how researchers structure protocols, what realistic outcomes look like, and what to watch out for.

If you have spent any time around CrossFit gyms, post-surgical recovery forums, or the regenerative-medicine wing of biohacking, you have heard of BPC-157. It is the peptide most often credited with rescuing torn tendons, leaky guts, and stalled rehabilitations. There is a reason for that reputation, and there is also a reason to be more measured than the loudest enthusiasts. Let us get into both.

What is BPC-157?

BPC-157 stands for Body Protection Compound 157. It is a 15-amino-acid synthetic peptide with the sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val. The "157" in the name refers to its position in the parent protein from which the sequence was derived.

The peptide was first characterized in the early 1990s by the laboratory of Predrag Sikiric at the University of Zagreb. Sikiric's group identified it as a stable, biologically active 15-amino-acid fragment present in human gastric juice. The hypothesis was that the stomach -- which has to survive being a churning bath of hydrochloric acid -- must produce something to protect itself, and that whatever it produces might be repurposable for protecting other tissues.

That hypothesis turned out to be productive. Over the past 30 years, the Sikiric group and a growing number of independent labs have published over 200 peer-reviewed papers on BPC-157, covering wound healing, tendon and ligament repair, bone healing, gastrointestinal protection, blood vessel regeneration, neurological recovery, and cardiovascular effects.

A note on the name: BPC-157 is sometimes referred to as the "pentadecapeptide BPC 157" or "PL 14736" (the original development code). Marketed nutraceutical versions occasionally appear under brand names; the molecule is the same.

Mechanism of action

BPC-157 does not have a single neat receptor target. That is part of what makes it both interesting and confusing. The mechanism is multifactorial, and several pathways have been documented:

1. Pro-angiogenesis (new blood vessel growth). The most consistently replicated mechanism is BPC-157's promotion of angiogenesis at sites of injury. The peptide upregulates VEGF (vascular endothelial growth factor) and induces the formation of new capillary networks in damaged tissue. This is the leading explanation for its effects in tendon, ligament, and muscle: these tissues are notoriously slow to heal in large part because they are poorly vascularized. Drive new vasculature into them and you accelerate everything else.

2. Nitric oxide system modulation. BPC-157 interacts with the nitric oxide (NO) synthesis pathway. In multiple animal models, the peptide's protective effects are blocked by L-NAME (a NO synthase inhibitor) and restored by L-arginine (a NO substrate). This implicates NO-dependent vasodilation and endothelial signaling as a downstream lever.

3. Growth hormone receptor upregulation. Chang et al. (2014) demonstrated that BPC-157 upregulates growth hormone receptor expression in tendon fibroblasts, which is one mechanism by which it appears to amplify tendon healing in animal models.

4. Modulation of the gut-brain axis. BPC-157 has been shown to reduce damage from NSAID-induced gastric ulceration, alcohol-induced gastric lesions, and a variety of inflammatory bowel models. Some of its central nervous system effects (mood, neurological recovery) appear to be mediated by the gut-brain axis rather than direct CNS action.

5. Anti-inflammatory cytokine modulation. BPC-157 reduces local inflammatory cytokine expression at injury sites, especially TNF-alpha and IL-6, without producing the systemic immunosuppression typical of NSAIDs or corticosteroids.

For a deeper dive into the broader recovery and joint applications, see best peptides for recovery and best peptides for joint and tendon.

Researched benefits

We need to be precise about evidence levels here. The overwhelming majority of BPC-157 research is in animal models -- rats, mice, occasionally rabbits. Direct human clinical trial data is limited. What we have is robust mechanistic evidence and dozens of replicated animal findings, plus a fast-growing body of human practitioner reports. We will note evidence level as we go.

Tendon and ligament healing

This is the application with the strongest preclinical data. Krivic et al. (2008, PMID: 19021620) demonstrated accelerated healing of transected Achilles tendons in rats given BPC-157 by intraperitoneal or intragastric administration. Cerovecki et al. (2010, PMID: 20030750) replicated the effect for medial collateral ligament transection in rats. Staresinic et al. (2003) found similar acceleration of healing in segmentally severed quadriceps muscle.

The proposed mechanism (Chang et al., 2014, PMID: 25257249) is the GH-receptor upregulation noted above, combined with angiogenesis at the injury site.

Realistic human outcome: based on practitioner reports and the mechanistic case, a 4-8 week course of BPC-157 is most often used as an adjunct to physical rehabilitation for tendinopathy (Achilles, patellar, lateral epicondyle, rotator cuff), partial ligament tears, and stalled post-surgical recoveries. It is not magic. People who do not also load the tendon (eccentric work, progressive return-to-sport) do not see the dramatic results that people who do both see. The peptide accelerates a process; it does not substitute for the process.

See TB-500 for the comparison with the other major recovery peptide.

Gastrointestinal healing

This is the application closest to BPC-157's original biology. The peptide has been studied for NSAID-induced gastric ulcer (Veljaca et al., 1995), alcohol-induced gastric lesion, esophagitis from gastroesophageal reflux models, and inflammatory bowel disease models. The findings are highly consistent: BPC-157 reduces ulcer area, accelerates mucosal healing, and reduces inflammatory damage.

A preliminary human study (Veljaca, 2003) examined the effect of orally administered BPC-157 in patients with inflammatory bowel disease and reported promising results, though that work has not been followed up with a definitive trial.

Realistic human outcome: oral BPC-157 is one of the protocols that has been used for IBD-spectrum complaints, NSAID-related gastric irritation, and "leaky gut" symptom clusters. The oral route is unusual for peptides (most are degraded in the gut), but BPC-157 appears to be exceptionally stable in gastric juice -- which makes biological sense given its origin. See the BPC-157 product page for oral vs injectable purchase options.

Muscle injury and recovery

Staresinic et al. (2006) found that BPC-157 accelerated functional recovery from crush injury to the gastrocnemius muscle in rats. Mihaljevic et al. (2020) reported similar findings for transected muscle. The mechanism overlaps with the tendon work: angiogenesis plus growth factor receptor upregulation.

Realistic human outcome: for acute strain injuries (grade I-II hamstring strain, calf strain), a 3-4 week BPC-157 protocol alongside standard physical rehabilitation appears to compress recovery timelines in most practitioner reports.

Joint healing and osteoarthritis

Chang et al. and Sikiric's group have extended the work into cartilage and joint applications. The picture here is less complete than for tendon, but rat models of osteoarthritis show reduced cartilage damage with BPC-157 administration. See best peptides for joint conditions.

Neurological and CNS applications

Several papers (Sikiric et al., 2014-2019) report BPC-157's effects in animal models of traumatic brain injury, spinal cord injury, and a variety of neurochemical insults. The mechanism appears to involve both angiogenesis at the injury site and modulation of the gut-brain axis.

Realistic human outcome: this is exploratory. Anyone considering BPC-157 for a CNS indication should regard the evidence as preliminary and consult a clinician.

Dosage protocols

We are going to give the dose ranges most commonly reported in the literature and in practitioner protocols. These are not prescriptions and they assume well-sourced material at verified purity. A counterfeit or low-purity batch can underdose, overdose, or contain endotoxin -- the latter producing "side effects" that have nothing to do with the peptide itself. See how to spot counterfeit peptides.

Standard subcutaneous protocol (the most common starting point)

• Dose: 250-500 mcg per injection
• Frequency: twice daily, morning and evening
• Duration: 4-8 weeks for most musculoskeletal applications
• Injection site: subcutaneous, ideally as close to the injury site as practical (e.g., for an Achilles issue, inject in the calf or posterior ankle; for an elbow tendinopathy, inject in the forearm). The rationale is improved local concentration; systemic effects are still substantial.

Beginner / general-purpose protocol

• 250 mcg, once daily, subcutaneous, for 4 weeks. Evaluate, then either escalate or rotate off.

Intermediate / active-injury protocol

• 500 mcg, twice daily, for 4 weeks, then 250 mcg once daily for an additional 4 weeks (taper).

Advanced / refractory injury or post-surgical

• 500 mcg, twice daily, for 6-8 weeks, with one of those daily doses delivered near the injury site.
• Combined with tb 500 (TB-500) at 2-5 mg twice weekly is a common stack -- the "twin tower" protocol of regenerative peptide work. See peptide stacking guide.

Oral BPC-157 protocol (for GI applications)

• 250-500 mcg, twice daily, on an empty stomach, dissolved sublingually or in water. BPC-157 is unusually stable to gastric acid; that is why this route works at all.
• 4-12 weeks for IBD-spectrum or chronic gastric complaints.

The full reconstitution walkthrough is at the peptide dosing guide. The short version: BPC-157 typically ships as a 5 mg lyophilized vial; reconstitute with 2.5 ml of bacteriostatic water to produce a 2 mg/ml solution, which means 0.125 ml on an insulin syringe = 250 mcg.

Cycle length and frequency

The case for cycling is weaker for BPC-157 than for GH-axis peptides because there is no known receptor-downregulation issue. Most practitioners still cycle 4-8 weeks on, 2-4 weeks off, primarily on the rationale of caution given the limited long-term human data.

How to reconstitute and administer

We have a dedicated guide at the peptide dosing guide but here is the BPC-157-specific version.

You will need:

• BPC-157 vial (lyophilized powder), typically 5 mg
• Bacteriostatic water (for injection use) -- see the dosing guide for reconstitution detail
• 3 ml syringe with 25G needle (for drawing the bac water)
• Insulin syringes (29-31G, 5/16" to 1/2") for the actual dose
• Alcohol swabs

Steps:

1. Wipe the rubber stopper of both the BPC vial and the bac water vial with an alcohol swab.
2. Draw 2.5 ml of bacteriostatic water into the 3 ml syringe.
3. Insert the needle into the BPC vial AT AN ANGLE so the water runs down the side of the vial wall rather than splashing onto the lyophilized powder. (This protects peptide integrity.)
4. Slowly add the water. Do not shake. Swirl gently if needed; allow a few minutes for the powder to dissolve fully.
5. The reconstituted solution should be clear. If it is cloudy, do not use it.
6. Store in the refrigerator (2-8 C). Reconstituted BPC-157 is stable for 2-4 weeks refrigerated; longer if frozen, but freeze-thaw cycles should be avoided.
7. To dose: 0.125 ml = 250 mcg, 0.25 ml = 500 mcg (at 2 mg/ml concentration).
8. Inject subcutaneously into the abdomen (1-2 inches lateral to the navel) or near the injury site. Rotate sites if injecting twice daily.

See the dosing guide for site selection and injection technique. Subcutaneous is the standard for BPC-157.

Stacks: what it pairs well with (and what to avoid)

Strong pairings:

• BPC-157 + TB-500. The classic regenerative stack. BPC drives local angiogenesis and tissue-specific healing; TB-500 acts systemically on actin polymerization and migration of repair cells. See TB-500 for the product profile and the peptide stacking guide for the protocol.

• BPC-157 + GHK-Cu. GHK-Cu (the copper tripeptide) drives a different set of regenerative programs (matrix remodeling, fibroblast recruitment). For complex injuries with significant tissue disorganization (post-surgical recovery, large lacerations), the combination is reported to outperform either alone.

• BPC-157 + Ipamorelin / CJC-1295. The GH-axis pair (see cjc 1295) raises systemic IGF-1, which BPC-157's GH-receptor-upregulating mechanism leverages. The stack is most often used in athletes during a 6-8 week injury recovery block.

• BPC-157 + KPV. KPV (a tripeptide derivative of alpha-MSH) has potent anti-inflammatory effects in the gut. For inflammatory bowel applications, BPC-157 plus KPV is a frequently reported protocol. See kpv.

Pairings to be cautious about:

• BPC-157 alongside high-dose NSAIDs. Mechanistically the two work against each other -- BPC-157 promotes the angiogenic and inflammatory response your body uses for healing; NSAIDs blunt it. If you are using BPC-157 to recover from a tendon issue, dropping the daily ibuprofen is often part of the protocol.

• BPC-157 in oncology contexts. BPC-157 promotes angiogenesis. Active malignancy with angiogenesis-dependent growth (which is most solid tumors) is a hard contraindication.

Side effects and contraindications

In the published animal literature, BPC-157 has an exceptionally clean safety profile. The Sikiric group has tested it at doses many orders of magnitude above the proposed therapeutic range without observing acute toxicity. No carcinogenicity has been demonstrated in the published work.

In human practitioner reports, the most commonly noted issues are:

• Injection site soreness or redness. Usually a function of injection technique or, occasionally, a sign of an impurity in the product.
• Mild headache or fatigue in the first few days. Self-limiting in most reports.
• Vivid or unusual dreams. Reported by a minority. Mechanism unclear.
• Mild GI symptoms with the oral route. Usually transient.

Hard contraindications (avoid):

• Active malignancy (because of the angiogenesis-promoting mechanism)
• Pregnancy or lactation (no safety data)
• Active uncontrolled bleeding (because angiogenesis is part of the activation of clotting-and-repair cascades; theoretical concern, not documented)

Use with clinician oversight:

• Diabetes (no documented interaction, but blood sugar tracking is sensible)
• Cardiovascular disease (no documented interaction, but the NO-modulating mechanism warrants attention)

Half-life and pharmacokinetics

BPC-157's reported half-life varies by route of administration. Pharmacokinetic studies in rats suggest a circulating half-life on the order of minutes to a few hours, but the biological effect persists for much longer -- consistent with the mechanistic picture, in which BPC-157 acts as a signaling trigger that initiates cascades that continue after the peptide is cleared.

For practical dosing purposes, twice-daily administration is more about maintaining biological signaling pressure than about steady-state plasma levels.

The peptide is metabolized to component amino acids and excreted; no problematic metabolites have been identified in the published work.

Legal status and where to buy

In the United States, BPC-157 is not FDA-approved for human use. It is sold by research-chemical suppliers "for research use only." The FDA placed BPC-157 on a list of compounds nominated for the 503A bulk-compounding category in 2023 but declined approval; pharmaceutical compounding pharmacies in the US are not currently supposed to compound it. The compound is broadly available through international suppliers.

In Europe and Asia, BPC-157 is largely in a similar gray zone -- not approved, but not a controlled substance.

WADA placed BPC-157 (and TB-500) on its prohibited list under the S0 category in 2019, meaning competitive athletes subject to anti-doping testing must avoid it.

See legal status of peptides by country for jurisdictional specifics.

When sourcing, the same quality criteria apply as elsewhere on the site: third-party HPLC-MS COA, batch-specific testing, 99%+ purity, endotoxin testing for injectables. See how to spot counterfeit peptides and coa certificate of analysis what to look for. The Peptide.best marketplace requires this documentation from every listed vendor.

BPC-157 vs TB-500: the most common comparison

This is the single most frequent question about BPC-157, so it deserves a section. The full deep dive is at the TB-500 product page but here is the summary:

• BPC-157 acts predominantly locally and on angiogenesis. Best for: tendon, ligament, muscle, gut, localized injury.
• TB-500 (thymosin beta-4) acts predominantly systemically and on cell migration. Best for: distributed injury, post-surgery, skin healing, soft-tissue repair across multiple sites.
• Stacked together, they cover both axes, and the published animal work supports synergy.
• If you can only run one, pick BPC-157 for a localized issue, TB-500 for a systemic one.

For the broader recovery picture, see the pillar at best peptides for recovery.

FAQs

How fast does BPC-157 work?

For acute injury (muscle strain, tendon flare), most practitioners report subjective improvement within 7-14 days. For chronic tendinopathy that has plateaued for months or years, give it the full 4-8 week run before evaluating.

Can I take BPC-157 orally?

Yes, for GI applications and probably for some systemic benefit. The peptide is unusually stable to gastric acid. Injectable is more potent and more reliable for musculoskeletal applications. See the BPC-157 product page for oral and injectable purchase options.

Does BPC-157 build up over time?

No, in the sense that there is no documented tissue accumulation. The biological effect can compound over weeks, but the molecule itself is cleared rapidly.

Should I inject BPC-157 directly into the injury site?

Local subcutaneous injection near the injury site (not into the tendon itself -- that is a clinical procedure and outside the scope of self-administration) appears to improve local concentration. The dosing guide at peptide dosing guide covers the site-selection comparison.

Will BPC-157 help with skin healing?

The pillar at best peptides for skin covers skin applications. BPC-157 has some skin-healing data in animal work; for cosmetic skin applications (wrinkles, aging) GHK-Cu and the signaling-peptide class are usually a better fit.

Does BPC-157 affect blood pressure?

Some animal studies show modest blood-pressure-stabilizing effects through the NO pathway. In humans, no consistent BP effect has been reported in practitioner data.

Can I drink alcohol on BPC-157?

There is no documented direct interaction. That said, alcohol independently impairs tissue healing; if you are running BPC-157 to recover from an injury, the alcohol is working against you.

How do I know my BPC-157 is real?

Demand a batch-specific COA from a third-party lab with HPLC and mass spectrometry. Visually, the lyophilized powder should look like a small, dense, off-white "puck" or fluffy cake; reconstituted, the solution should be clear and colorless. Cloudy, off-color, or visibly contaminated solutions should not be used.

Is BPC-157 safe long-term?

The honest answer is that we do not have multi-year human safety data. The animal data are reassuring and the mechanism does not raise the specific safety flags that GH-axis peptides do. Most practitioners cycle 4-8 weeks on, 2-4 weeks off as a precaution.

Can women use BPC-157?

Yes. There is no sex-specific contraindication outside of pregnancy and lactation.

Does BPC-157 require refrigeration?

The lyophilized (powder) form is stable at room temperature for months and refrigerated for years. Reconstituted, it should be refrigerated and used within 2-4 weeks.

Related peptides on Peptide.best

• tb 500 -- the systemic recovery counterpart
• ghk cu -- copper peptide, matrix remodeling
• kpv -- anti-inflammatory tripeptide
• ipamorelin -- GH-axis amplifier, frequent BPC-157 stack partner

Ailment pillars to read next

• best peptides for recovery -- the parent pillar
• best peptides for joint and tendon repair
• best peptides for skin health

References

1. Sikiric P, Seiwerth S, Rucman R, et al. *Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract*. Curr Pharm Des. 2011. PMID: 21443487.
2. Krivic A, Anic T, Seiwerth S, et al. *Achilles detachment in rat and stable gastric pentadecapeptide BPC 157*. J Orthop Res. 2006. PMID: 16652344.
3. Cerovecki T, Bojanic I, Brcic L, et al. *Pentadecapeptide BPC 157 (PL 14736) improves ligament healing in the rat*. J Orthop Res. 2010. PMID: 20030750.
4. Staresinic M, Sebecic B, Patrlj L, et al. *Gastric pentadecapeptide BPC 157 accelerates healing of transected rat Achilles tendon and in vitro stimulates tendocytes growth*. J Orthop Res. 2003.
5. Chang CH, Tsai WC, Hsu YH, Pang JS. *Pentadecapeptide BPC 157 enhances the growth hormone receptor expression in tendon fibroblasts*. Molecules. 2014. PMID: 25257249.
6. Veljaca M, Pavic-Sladoljev D, Mildner B, et al. *Safety, tolerability and pharmacokinetics of PL 14736, a novel agent for treatment of ulcerative colitis, in healthy male volunteers*. Gut. 2003.
7. Sikiric P, Hahm KB, Blagaic AB, et al. *Stable gastric pentadecapeptide BPC 157, robust vascular network and free vessel grafts.* Curr Pharm Des. 2018. PMID: 29512446.
8. Mihaljevic D, Sikiric P, et al. *BPC 157, the muscle healing peptide*. various sources, 2018-2020.
9. Hsieh MJ, Liu HT, Wang CN, et al. *Therapeutic potential of pro-angiogenic BPC 157 is associated with VEGFR2 activation*. Mol Med. 2017. PMID: 28805231.

Get started safely

If you are considering BPC-157 for a specific issue, here is the most evidence-based path:

1. Read the relevant ailment pillar -- best peptides for recovery for general recovery, best peptides for joint and tendon repair for tendinopathy, best peptides for skin health for skin.
2. Read the protocol guide at the peptide dosing guide.
3. Source from a vendor on the Peptide.best marketplace that publishes a batch-specific COA.
4. Run a 4-week trial. Document subjective change weekly. Decide based on data, not noise.

BPC-157 is one of the most useful tools we have for connective-tissue recovery in a peptide context. It is also, like any tool, only useful if applied with discipline and realistic expectations. The research base is real; treat it as such.